brain cancer ͉ microarray U sing the tools of global expression profiling, it has become possible to classify many tumors from the same site of origin into distinct clinical subgroups, to implicate genes involved in tumor formation and progression and to define patients with distinct prognoses (1) (2) (3) (4) (5) (6) . Expression profiling can also define signatures of specific signaling pathways, such as those of Myc, Ras, and other oncogenes (7, 8) . Moreover, gene expression signatures have been mined to yield functional linkages, such as the role of C/EBP␤/NfIl6 transcription factor in cyclin D1 overexpression (9) .
One challenge in the clinical development of molecularly targeted cancer therapy is the selection of appropriate patients, i.e., those whose tumors reflect alterations in the specific pathways to be targeted. The feasibility of conducting large-scale clinical trials in such molecularly defined populations would be greatly facilitated by the availability of serum biomarkers that might reflect the activation state of a signaling pathway in the tumor. Prostate-specific antigen is one example of such a pathway biomarker, because it reflects activation of the androgen receptor and serves as an excellent readout for the efficacy of antiandrogen therapy in men with hormone-refractory prostate cancer (10) . Here we have used global expression profiling in a cohort of human glioblastoma and prostate samples annotated for PTEN status to define a molecular signature that might include biomarkers with clinical utility.
PTEN is a tumor-suppressor gene implicated in multiple human cancers through mutation, homozygous deletion, loss of heterozygosity, or epigenetic loss of expression (11) (12) (13) . Among the most cancers most commonly affected by PTEN abnormalities are glioblastoma, prostate, and endometrial tumors, with frequencies approaching 50% (14) . Germline PTEN mutations are found in two autosomal-dominant cancer predisposition syndromes (14, 15) . Homozygous deletion of the PTEN gene in mice is lethal, and heterozygous deletion results in tumor formation in several organs (16) (17) (18) . The best characterized biochemical function for the PTEN protein is its lipid phosphatase activity against phosphatidylinositol triphosphate (PIP3), the product of phosphoinositide 3-kinase (PI3K) activation in response to many growth factors implicated in tumor formation (18, 19) . This PI3K-antagonizing activity in turn inhibits activation of the downstream effector Akt and leads to inhibition of cell survival and proliferation, cellular processes essential for tumor formation and progression (20) .
To identify transcriptional targets associated with PTEN loss, we performed microarray-based expression profiling with on a panel of human prostate cancer xenografts and human glioblastoma samples annotated for PTEN status by mutation analysis and protein expression. Because signaling networks are system-and contextdependent, we felt that it was important not to rely strictly on cell lines. Therefore we included xenografts, which consist of nearly homogeneous human tumor material, and archived clinical material selected for high human tumor cell content. Through this analysis we identified a nine-gene signature that accurately classified the tumor samples according to PTEN status regardless of tumor type. We also show that the most significant gene in the signature, insulin growth factor-binding protein 2 (IGFBP-2), is inversely regulated by PTEN in isogenic models and required for Akt-mediated fibroblast transformation. Interestingly, elevated serum IGFBP-2 levels have been reported in patients with prostate cancer and glioblastoma, as well as other cancers such as colorectal, ovarian and acute lymphoblastic leukaemia (21-24), but not previously linked to PTEN status. Therefore, our findings raise the possibility that serum levels of IFGBP-2, likely in conjunction with the measurement of other markers, could serve as a biomarker of PTEN status in patients with prostate cancer, glioblastoma or perhaps other cancers with abnormalities in the PI3K/PTEN/Akt pathway.
Results

A Nine-Gene mRNA Classifier for Loss of the PTEN Tumor-Suppressor
Gene. To identify transcriptional targets associated with PTEN tumor-suppressor function, we compared the gene expression profiles of 11 tissue or xenograft samples that bear the wild-type PTEN gene to those of 14 samples with loss of PTEN function as defined by deletion, mutation, or loss of protein expression (Fig. 1) . These 25 samples included 12 advanced prostate cancer xenografts (reflecting six isogenic hormone-sensitive and hormone-refractory sublines) and 13 glioblastoma tissue samples. The PTEN status of the prostate cancer xenografts were characterized in ref. 25 . The glioblastoma samples were examined by Western blot analysis and genomic DNA sequence analysis. Six samples had no detectable PTEN protein expression and were classified as PTEN mutant. The other seven samples were classified as PTEN wild type on the basis of easily detected PTEN protein expression and the absence of point mutations, as determined by genomic DNA sequence analysis (data not shown).
The expression profiles of all 25 prostate cancer and glioblastoma samples were analyzed by using a random forest (RF) prediction method to identify a tissue-independent signature that might classify the tumors by PTEN status (26) . As byproducts of its construction, an RF predictor yields a measure of variable importance which can be used to determine which gene expression values are most important for predicting the PTEN status (Fig. 1 A) . The larger the importance measure, then the more important the gene (or probe set) is for predicting PTEN status. The results obtained through RF analysis were consistent with those obtained by using other methods such as the Kruskal-Wallis test of differential expression (Fig. 1 A) and the Student t test [supporting information (SI) Appendix]. The apparent error rate of the RF predictor can be measured as a function of the number of probe sets used to make the class distinction. For the 10 most important probe sets, the apparent error rate of the RF fell to zero (Fig. 1B) . IGFBP-2 is represented twice in this top-10 list (by two independent probe sets), thus the classifier contains only nine genes. As an alternative gene-filtering method, we used the Kruskal-Wallis test, a nonparametric multigroup comparison test, to determine genes that are differentially expressed between wild-type and mutant PTEN samples. These same 10 probe sets are significantly differentially expressed (P Ͻ 0.0075) and are among the 30 most differentially expressed probe sets (SI Appendix and Tables 1 and 2 Microarrays were used to measure the expression profiles of 25 prostate cancer xenograft and glioblastoma samples, of which 11 were classified PTEN wild type and 14 were classified PTEN mutant. To relate PTEN status to the gene expression data, we used RF predictors and the Kruskal-Wallis test of differential expression. An RF importance measure was used to rank probe sets according to their prognostic importance for PTEN status. (A) The RF variable importance measure is highly correlated (r ϭ 0.28) with a conventional measure of differential expression (minus log 10 of the Kruskal-Wallis test P value). In the SI Appendix, we also consider alternative variable importance measures and the Student t test. We find that our results are highly robust with respect to the gene screening method. (B) The error rate of the RF predictor as a function of the number of most important probe sets. We find that the 10 most important probe sets lead to an apparent error rate of zero. (C) Classical multidimensional scaling plot for visualizing the dissimilarities between the microarray samples (on the basis of the 10 most important probe sets). Prostate cancer samples are labeled ''P,'' and glioblastoma samples are labeled ''B.'' PTEN mutant samples are in orange, and wild type is in cyan (turquoise). The plot in C and the supervised hierarchical clustering plot (D) show that the 10 most important probe sets stratify the samples according to their PTEN status.
ability of the 10 probes to classify tumor samples with different PTEN status can also be visualized by a multidimensional scaling plot (Fig. 1C) and by supervised hierarchical clustering (Fig. 1D) . Thus, we find that these nine genes can separate PTEN mutant from PTEN wild-type tumors in this data set regardless of where the cancer originated (glioblastoma or prostate cancer).
Elevated Levels of IGFBP-2 Protein Expression in PTEN Mutant Tumors.
We next examined the link between PTEN loss and up-regulation of IGFBP-2, the most significant gene in the classifier, at the protein level. Using lysates available from 10 prostate cancer xenografts and 24 glioblastoma tissue samples, we found increased levels of IGFBP-2 protein in all PTEN-null tumors. This analysis included four prostate xenografts and 10 glioblastomas that were not part of the original test set from which the nine-gene signature was derived ( Fig. 2 A and B and SI Table 3 ). Glioblastoma sample 429 was notable because a high level of IGFBP-2 protein expression was observed despite wild-type PTEN status. Western blot analysis indicated high levels of Akt activation as measured by using the phospho-specific pSer473 antibody (data not shown), suggesting that Akt is activated by a mechanism other than PTEN mutation in this sample. This finding also raises the possibility that Akt activation is responsible for elevated expression of IGFBP-2 in PTENnull cancers.
Because IGFBP-2 is a secreted protein, we asked whether elevated levels are detected in the supernatants of PTEN-null cell lines grown in culture. In a panel of six cell lines, including two each from prostate, glioblastoma, and breast cancer, IGFBP-2 levels measured by RIA were higher in the three PTEN-null lines (Ͼ70 ng/ml) than in the three PTEN wild-type lines (Ͻ20 ng/ml) when normalized for confluency (Fig. 2C) . We extended these findings to xenograft models of prostate and breast cancer, detecting elevated serum levels of human IGFBP-2 in mice bearing s.c. PTEN-null tumors, but not PTEN wild-type tumors (Fig. 2D) . Therefore, human tumors with PTEN mutations (including breast cancer) secreted high levels of IGFBP-2, which might serve as a serum biomarker for PTEN status.
Inhibition of IGFBP-2 Expression by PTEN.
To examine the molecular basis for the PTEN/IGFBP2 link, we extended our analysis to isogenic mouse embryonic fibroblasts (MEFs) isolated from PTEN knockout mice (27) . Consistent with the human tumor findings, IGFBP-2 protein expression was substantially higher in PTEN Ϫ/Ϫ MEFs (Fig. 3A) . To determine whether up-regulation of IGFBP-2 expression in PTEN-null cells depends on the PI3K/Akt pathway, we treated PTEN mutant LnCaP prostate cancer cells with the PI3K inhibitor LY294002. IGFBP-2 levels fell to baseline in drugtreated cells in parallel with reduced levels of Akt phosphorylation (Fig. 3B) . Because LY294002 can inhibit other targets in addition to PI3K, we also pursued a genetic approach to address the PTEN/IGFBP-2 link. Whereas LY294002 lowered IGFBP-2 levels in PTEN-null cells, increased levels of IGFBP-2 expression were observed in PTEN wild-type DU145 prostate cancer cells infected with retrovirus expressing a constitutively active Akt allele (HAMyr-Akt) (Fig. 3C) . These results indicate that IGFBP-2 expression is induced by PI3K/Akt pathway activation and antagonized by the PTEN tumor suppressor.
Functional Role of IGFBP-2 in PTEN/Akt Signaling. IGFBP-2 functions as an insulin-like growth factor 1 (IGF1) binding protein and, in certain contexts, enhances the agonist effects of IGF1 on the IGF1 receptor (IGF1R) (28) . Because IGF1R potently activates the PI3K/Akt pathway, one could envision a model in which the increased levels of IGFBP-2 observed in PTEN-null cells might play a functional role, perhaps by enhancing positive input to PI3K. To explore a potential functional link between IGFBP-2 and PTEN, we asked whether overexpression of IGFBP-2 in PTEN-null cells treated with a PI3K inhibitor might rescue any of the biological effects of PI3K inhibition. As expected, LY294002 treatment reduced the fraction of PTEN-null LnCaP prostate cancer cells in S phase and lowered IGFBP-2 levels. This reduction in S phase was partially rescued by the forced expression of exogenous IGFBP2, whereas IGFBP-2 expression had no measurable effect in the absence of LY294002 (Fig. 4A) . We further addressed the functional role of IGFBP-2 by using IGFBP-2 Ϫ/Ϫ MEFs. Infection of IGFBP-2 ϩ/ϩ MEFs with HA-Myr-Akt retrovirus led to focus formation when plated on plastic at limiting dilution and quantified by crystal violet visualization. The number of foci was reduced substantially in IGFBP-2 Ϫ/Ϫ MEFs despite comparable levels of HA-Myr-Akt expression (Fig. 4B) active Akt to promote focus formation in IGFBP-2 Ϫ/Ϫ MEFs was partially rescued by reintroduction of IGFBP-2 (Fig. 4B) . Furthermore, the requirement of IGFBP-2 was specific to Akt because focus formation was observed in IGFBP-2 ϩ/ϩ and IGFBP-2
MEFs at comparable levels after infection with c-Myc retrovirus (Fig. 4C ). These data suggest that increased IGFBP-2 levels, in addition to serving as a potential biomarker of PTEN loss, may also play a functional role. The mechanism by which IGFBP-2 might promote PI3K/Akt pathway transformation requires much further work. Although one possibility is a feed-forward loop through enhanced IGF1R activation, IGFBP-2 can also regulate the expression of genes involved in tumor invasion (29) .
Discussion
We report here that nine genes serve as a classifier of PTEN status in a defined set of human glioblastoma samples and human prostate cancer xenografts. The most significant among them is the secreted protein IGFBP-2 (P ϭ 7.5 ϫ 10 Ϫ7 ), which has been independently shown to be up-regulated in glioblastoma and prostate tumors with poor prognosis but not previously linked to PTEN status (30, 31) .
Other Genes in the PTEN Classifier. Although the focus of this report is on IGFBP-2, it is worth noting that several of the other eight genes in the PTEN classifier also have plausible biological roles in PI3K/Akt pathway function and may be worthy of further investigation. For example, Neuralized Drosophila-like is an E3 ligase for the Notch signal transduction pathway and mediates proteosomedependent degradation of the Notch ligand Delta (32) . Therefore, reduced levels of Neuralized, as seen in PTEN-null tumors, would be expected to lead to enhanced Notch activation, which is associated with many cancer phenotypes (33, 34) . Indeed, loss-offunction mutations of the neurogenic genes produce hyperplasia of the embryonic nervous system in flies (35) , somewhat analogous to the brain phenotype of the brain-specific PTEN knockout mice (36) . Furthermore, Neuralized is highly expressed in normal human brain tissue but is low or absent in advanced gliomas (37) . Another classifier gene of interest is dual-specificity phosphatase 10 (also called MAPK phosphatase-5 or MKP-5), which selectively dephosphorylates JNK and reduces its activity (38) . The microarray data show that DSP-10/MKP-5 levels are reduced in PTEN-null tumors, suggesting that JNK activity may be increased in PTEN- null cancers. A third gene in the classifier, Regulator of G protein signaling 1, is noteworthy because it specifically binds to and is inhibited by the PTEN substrate phosphatidylinositol triphosphate (PIP3) (39, 40) , raising the possibility of feedback control of PI3K signaling.
IGFBP-2 as a Potential Biomarker of PTEN Status. Our identification of IGFBP-2 up-regulation in PTEN-null glioblastomas and prostate cancers is consistent with prior reports examining IGFBP-2 levels in tumor samples and in patient sera (41) . For example, IGFBP-2 overexpression was observed in up to 50% of glioblastomas but not in lower-grade astrocytomas and was associated with a worse prognosis (42, 43) . The frequency and prognostic impact of IGFBP-2 overexpression in glioblastoma are remarkably similar to similar statistics on PTEN loss (44), consistent with the notion raised here that these events are linked. Indeed, while this work was underway, another group reported that IGFBP-2 protein level is regulated by PTEN in glioblastoma cells but did not define the mechanism (45) . Further studies are required that use larger, independent data sets annotated for PTEN status to determine whether the nine-gene classifier and particularly IGFBP-2 serum levels can serve as clinical biomarkers of PTEN status.
Potential Utility of Pathway Biomarkers in Clinical Trials
. A large number of signaling pathway inhibitors are currently entering the clinic and are anticipated to have activity in subsets of patients, primarily those with abnormalities in the molecularly targeted pathway of interest. On the basis of the frequency of PTEN and PI3K pathway mutations in a broad range of tumor types, inhibitors of this pathway have been an area of intense interest. However, successful clinical development requires tools that permit classification of patients on the basis of these molecular lesions. Tumor genotyping will undoubtedly figure prominently in solving this problem, but companion serum markers that reflect the activation state of a particular signaling pathway could prove invaluable in classifying patients and in monitoring response to pathway-specific therapy. IGFBP-2 serum levels may be such a tool to monitor response to PI3K pathway inhibitors, analogous to the effects we observed here in PTEN-null model systems. Of note, others have observed that Hsp90 inhibitors, which promote Akt protein degradation (among other effects), lower IGFBP-2 serum levels in xenograft models (46) . Conversely, elevated IGFBP-2 serum levels have been implicated as a biomarker for treatment with recombinant IGF1, which activates IGF1R and the PI3K/Akt pathway (47) . In summary, we report here that PTEN status is inversely correlated with IGFBP-2 expression in prostate cancer xenografts and clinical glioblastoma samples and propose that serum IGFBP-2 levels may be a biomarker for PI3K/Akt pathway activation in patients with PTEN-null cancers.
Methods
Prostate Cancer Xenografts. All of the prostate cancer xenografts (LAPC9, LUCaP 35, LAPC4, LUCaP23, LAPC3, LAPC12, LUCaP41, and LAPC14) were derived from patients that had local advanced or metastatic prostate cancer (48) . The human specimens were implanted into the flanks of severe combined immunodeficient or nude mice in serial passages to enrich for homogenous populations of prostate cancer cells. Microarray expression profiling data from some of these xenografts were reported in a study of mechanisms of hormone refractory growth (49) . Animals were maintained in accordance with institutional guidelines. The PTEN status of the prostate cancer xenografts was characterized in ref. 25 .
Glioblastoma Samples. To exclude any potential effect of treatment on gene expression, we studied glioblastoma multiforme (GBM) from untreated patients that had developed de novo (primary GBM) and from which high-quality RNA could be obtained. Tables 1 and 2 .
The SI Appendix also serves as a tutorial for RF analysis with the R software. The .CEL files for all of the microarray hybridizations (27 samples) generated by Affymetrix Microarray Suite Software were imported into the software dChip (50) . All arrays were normalized against the array with median overall intensity. We used dChip to compute model-based expression indices (perfect match minus mismatch). To predict PTEN status on the basis of gene expression profiles, we used the RF predictors by Breiman (26) . As a byproduct of its construction, an RF predictor yields an estimate of its error rate, a dissimilarity measure between the samples, and measures of variable importance. A measure of variable importance can be used to determine which genes are most important for predicting the tumor class. We chose the node purity-based importance measure (mean decrease in the Gini index). In the SI Appendix, we demonstrate that our findings are highly robust with respect to the choice of importance measure or choice of differential expression test. Specifically, we also considered the KruskalWallis test, which is a nonparametric group comparison test and the Student t test of differential expression. As input of the classical multidimensional scaling plot (Fig. 1C) and average linkage hierarchical clustering analysis (Fig. 1D) , we used the supervised RF dissimilarity measure that results from predicting PTEN status with the top 10 most important probe sets.
Serum from Mice Carrying Human Prostate and Breast Cancer Xenografts. The animals were bled either retro-orbitally or by cardiac puncture. Blood samples were centrifuged at 2,000 ϫ g for 5 min, and serum was collected and stored at Ϫ80 C. 
